AC Immune SA ACIU.OQ ACIU.O is expected to show a fall in quarterly revenue when it reports results on March 12 (estimated) for the period ending December 31 2024
The Lausanne Vaud-based company is expected to report a 95.0% decrease in revenue to CHF742.09 thousand from CHF14.8 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for AC Immune SA is for a loss of 19 rappen per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for AC Immune SA is $8.50, above its last closing price of $2.41.
Previous quarterly performance (using preferred earnings measure in Swiss francs).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.19 | -0.20 | 0.05 | Beat | 125.5 |
Jun. 30 2024 | 0.35 | 0.27 | -0.23 | Missed | -185.4 |
Mar. 31 2024 | -0.13 | -0.14 | -0.18 | Missed | -33.2 |
Dec. 31 2023 | -0.06 | -0.11 | -0.05 | Beat | 55.9 |
Sep. 30 2023 | -0.07 | 0.03 | -0.18 | Missed | -801.2 |
Jun. 30 2023 | -0.19 | -0.20 | -0.20 | Met | -1.4 |
Mar. 31 2023 | -0.23 | -0.23 | -0.21 | Beat | 8.5 |
Dec. 31 2022 | -0.25 | -0.23 | Beat | 8.7 |
This summary was machine generated March 10 at 12:32 GMT. All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.